- 专利标题: Biocompatible polycaprolactone fumarate formulations
-
申请号: US14009987申请日: 2012-04-04
-
公开(公告)号: US10426867B2公开(公告)日: 2019-10-01
- 发明人: Michael Brett Runge , Michael J. Yaszemski
- 申请人: Michael Brett Runge , Michael J. Yaszemski
- 申请人地址: US MN Rochester
- 专利权人: Mayo Foundation for Medical Education and Research
- 当前专利权人: Mayo Foundation for Medical Education and Research
- 当前专利权人地址: US MN Rochester
- 代理机构: Quarles & Brady LLP
- 国际申请: PCT/US2012/032131 WO 20120404
- 国际公布: WO2012/138732 WO 20121011
- 主分类号: A61L27/18
- IPC分类号: A61L27/18 ; A61L27/26 ; C08G63/08 ; C08G63/60
摘要:
A polycaprolactone fumarate polymer useful as a matrix material for a biocompatible scaffold for tissue engineering applications is disclosed. The polycaprolactone fumarate polymer can be prepared by reacting caprolactone with an alkane polyol to prepare a polycaprolactone precursor, and then reacting the polycaprolactone precursor with fumaric acid or a salt thereof to prepare the polycaprolactone fumarate polymer. The use of an alkane diol, such as 1,2-propanediol, provides a linear polycaprolactone diol precursor. The use of an alkane triol, such as glycerol, provides a branched polycaprolactone triol precursor. The biocompatible polycaprolactone fumarate formulation releases no diethylene glycol or other undesirable byproducts during degradation.
公开/授权文献
- US20140099278A1 BIOCOMPATIBLE POLYCAPROLACTONE FUMARATE FORMULATIONS 公开/授权日:2014-04-10
信息查询